300 related articles for article (PubMed ID: 33239387)
41. Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds.
Remnestål J; Bergström S; Olofsson J; Sjöstedt E; Uhlén M; Blennow K; Zetterberg H; Zettergren A; Kern S; Skoog I; Nilsson P; Månberg A
Alzheimers Res Ther; 2021 Mar; 13(1):54. PubMed ID: 33653397
[TBL] [Abstract][Full Text] [Related]
42. Upregulation of RIN3 induces endosomal dysfunction in Alzheimer's disease.
Shen R; Zhao X; He L; Ding Y; Xu W; Lin S; Fang S; Yang W; Sung K; Spencer B; Rissman RA; Lei M; Ding J; Wu C
Transl Neurodegener; 2020 Jun; 9(1):26. PubMed ID: 32552912
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
[TBL] [Abstract][Full Text] [Related]
44. Impaired axonal retrograde trafficking of the retromer complex augments lysosomal deficits in Alzheimer's disease neurons.
Tammineni P; Jeong YY; Feng T; Aikal D; Cai Q
Hum Mol Genet; 2017 Nov; 26(22):4352-4366. PubMed ID: 28973312
[TBL] [Abstract][Full Text] [Related]
45. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
[TBL] [Abstract][Full Text] [Related]
46. The use of proteomics in biomarker discovery in neurodegenerative diseases.
Davidsson P; Sjögren M
Dis Markers; 2005; 21(2):81-92. PubMed ID: 15920295
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
[TBL] [Abstract][Full Text] [Related]
48. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
49. Increased cerebrospinal fluid tau in patients with Alzheimer's disease.
Jensen M; Basun H; Lannfelt L
Neurosci Lett; 1995 Feb; 186(2-3):189-91. PubMed ID: 7777193
[TBL] [Abstract][Full Text] [Related]
50. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
[TBL] [Abstract][Full Text] [Related]
51. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
[TBL] [Abstract][Full Text] [Related]
52. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.
Ishiguro K; Ohno H; Arai H; Yamaguchi H; Urakami K; Park JM; Sato K; Kohno H; Imahori K
Neurosci Lett; 1999 Jul; 270(2):91-4. PubMed ID: 10462105
[TBL] [Abstract][Full Text] [Related]
53. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
54. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
[TBL] [Abstract][Full Text] [Related]
55. Hyperconnectivity of Self-Referential Network as a Predictive Biomarker of the Progression of Alzheimer's Disease.
Yao W; Chen H; Luo C; Sheng X; Zhao H; Xu Y; Bai F;
J Alzheimers Dis; 2021; 80(2):577-590. PubMed ID: 33579849
[TBL] [Abstract][Full Text] [Related]
56. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
[TBL] [Abstract][Full Text] [Related]
57. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.
Suárez-Calvet M; Karikari TK; Ashton NJ; Lantero Rodríguez J; Milà-Alomà M; Gispert JD; Salvadó G; Minguillon C; Fauria K; Shekari M; Grau-Rivera O; Arenaza-Urquijo EM; Sala-Vila A; Sánchez-Benavides G; González-de-Echávarri JM; Kollmorgen G; Stoops E; Vanmechelen E; Zetterberg H; Blennow K; Molinuevo JL;
EMBO Mol Med; 2020 Dec; 12(12):e12921. PubMed ID: 33169916
[TBL] [Abstract][Full Text] [Related]
58. Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.
Alexopoulos P; Guo LH; Tsolakidou A; Kratzer M; Grimmer T; Westerteicher C; Jiang M; Bujo H; Diehl-Schmid J; Kurz A; Perneczky R
J Alzheimers Dis; 2012; 28(3):543-52. PubMed ID: 22045485
[TBL] [Abstract][Full Text] [Related]
59. Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease.
Schirinzi T; Di Lazzaro G; Sancesario GM; Colona VL; Scaricamazza E; Mercuri NB; Martorana A; Sancesario G
J Neural Transm (Vienna); 2017 Dec; 124(12):1621-1625. PubMed ID: 28866757
[TBL] [Abstract][Full Text] [Related]
60. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
